Individualizing Therapy and Optimizing Treatments in MS

A series of Live Grand Rounds Programs and an On-demand Webcourse

Welcome to "Individualizing Therapy and Optimizing Treatments in MS.” This CME-certified initiative is intended for neurologists, MS specialists, primary care physicians, and other health care professionals who manage patients with multiple sclerosis. A series of live CME-certified programs will be presented at selected hospitals and an online CME-certified webcourse will be available in Spring 2016.

Program Description

The National Multiple Sclerosis Disease Management Consensus Statement recommends continuous use of disease-modifying drug (DMD) therapy, with initiation of a DMD as soon after definitive diagnosis as possible, and to also consider DMD therapy in select high-risk patients with a first attack. This push for earlier diagnosis and earlier initiation of DMD therapy has made MS management increasingly difficult. The ongoing emergence of new DMD therapies with different mechanisms of action and efficacy and safety profiles contributes to this complexity, as do the continuing scientific advances in MRI parameters and biomarkers research. These changes impact not only ongoing management, but patient counseling and long-term DMD decision-making as well, making MS management increasingly difficult.

Individualizing Therapy and Optimizing Treatments in MS will provide clinicians with education on the latest advances in the diagnosis and management of multiple sclerosis, so they can improve the care they provide to their MS patients.

Learning Objectives:

At the conclusion of this activity, participants should be able to demonstrate the ability to:

  • Incorporate the latest MRI criteria and other prognostic measures to improve diagnosis and initiate DMD therapy earlier in the course of MS
  • Assess the mechanisms of action and efficacy and safety profiles of current and emerging DMD therapies to develop individualized MS therapies that optimize adherence and improve patient outcomes
  • Utilize evidence from recent diagnostic and prognostic biomarker studies to improve monitoring of disease activity and response to DMD therapy in MS
Accreditation Statements:

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Potomac Center for Medical Education and Rockpointe. The Potomac Center for Medical Education is accredited by the ACCME to provide continuing medical education for physicians.

Designation Statements:

Physicians - The Potomac Center for Medical Education designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

For information about the accreditation of this program, please email contact@potomacme.org.

Physician Assistants - The American Academy of Physician Assistants accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME or a recognized state medical society. Physician assistants may receive a maximum of 1.0 hours of Category I credit for completing this program.

Nurse Practitioners - The American Academy of Nurse Practitioners accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME or a recognized state medical society. Nurse practitioners (and CNMs) may receive a maximum of 1.0 hours of Category I credit for completing this program.

Live Program Calendar:

If you are interested in attending a meeting in your local area, please contact Alexis Haley at 443-909-7907 or cbeavan@rockpointe.com for the schedule.

Live Program Calendar:

Back to Top

Related Online Offerings

>Click here to access the CME-certified webcourse associated with this program. (Coming soon)

Click here to access the CME-certified webcourse associated with this program.

Live Program Materials for Speakers and Administrators

Back to Top

I. Administrator Material

II. Speaker Material

Audio Orientation

Thank you for joining us as an expert speaker for the 2016 Grand Rounds series, “Individualizing Therapy and Optimizing Treatments in MS." This orientation will familiarize you with the complete slide set, provide insight from the program steering committee, and address potential questions. During the audio lecture, the following key topics will be discussed:

  • The latest MRI criteria and other prognostic measures
  • Mechanisms of action and efficacy and safety profiles of current and emerging DMD therapies
  • Recent diagnostic and prognostic biomarker studies

Transcript of Speaker Orientation Download (PDF) [Coming Soon]

Transcript of Speaker Orientation Download (PDF)

Audio download of Speaker Orientation Audio [Coming Soon]

Audio download of Speaker Orientation

Audio Download

CME-certified Program Slides

This version of the program slides has been CME-certified and these slides are to be used for this activity. Download (PowerPoint) [Coming Soon]

This version of the program slides has been CME-certified and these slides are to be used for this activity. Download (PPT)

Steering Committee Biographies

All steering committee and speaking faculty disclosures will be provided onsite in program syllabi distributed to all grand rounds participants.

Suhayl Dhib-Jalbut, MD Suhayl Dhib-Jalbut, MD

Professor and Chairman, Departments of Neurology
Rutgers-New Jersey Medical School and -Robert Wood Johnson Medical School
Chief, Neurology Service
Robert Wood Johnson University Hospital
New Brunswick, NJ

Suhayl Dhib-Jalbut, MD is Professor and Chairman of the Departments of Neurology at Rutgers-New Jersey Medical School and Rutgers-Robert Wood Johnson (RWJ) Medical School, and also serves as Director of the RWJ Center for Multiple Sclerosis (MS). Dr. Dhib-Jalbut currently serves as President of the Americas Committee for Treatment and Research in MS (ACTRIMS).

Dr. Dhib-Jalbut graduated Alpha-Omega-Alpha from the American University of Beirut in Lebanon and completed his training in neuroimmunology and multiple sclerosis at the National Institutes of Health.

Dr. Dhib-Jalbut’s research, funded by the NIH, the National MS Society, and industry sources, includes how MS therapies work, biomarkers of treatment response in MS, and neuroprotective gene therapy. Dr. Dhib-Jalbut has published more than 130 manuscripts in the scientific literature. He served on several national and international scientific committees including Chairmanship of the Scientific Committee for the World Congress on MS in 2008 and presided over the same congress in Boston in 2014.

Dr. Dhib-Jalbut has received several awards and recognitions, including the Norman H. Edelman Clinical Science Mentoring Award at Rutgers, the Musical Moments Medical Excellence Award by the National MS Society, the Edward Ill Award for Excellence in Clinical Research, and the NJ Foundation Excellence in Research Award.

Aaron E. Miller, MD Aaron E. Miller, MD

Professor of Neurology
Icahn School of Medicine at Mount Sinai
Medical Director
The Corinne Goldsmith Dickinson Center for Multiple Sclerosis
Mount Sinai Medical Center
New York, NY

Aaron E. Miller, MD is Professor of Neurology at the Icahn School of Medicine at Mount Sinai and Medical Director at the Corinne Goldsmith Dickinson Center for Multiple Sclerosis. He is widely recognized for his preeminence as an MS clinician and thought-leader.

Dr. Miller graduated from Brandeis University in 1964 and received his medical doctorate from New York University School of Medicine in 1968. Following his residency in neurology at the Albert Einstein College of Medicine, he received additional postdoctoral training in neurovirology and immunology at the Johns Hopkins University School of Hygiene and Public Health and at Einstein. During this time, he was the recipient of a fellowship from the National MS Society. In 2004, Dr. Miller assumed the position of Medical Director of the Corinne Goldsmith Dickinson Center for Multiple Sclerosis at the Mount Sinai School of Medicine. For 23 years prior, he headed the Division of Neurology at Maimonides Medical Center in Brooklyn, NY, where he continues to serve as Co-director of the MS Care Center.

Dr. Miller has been the Chief Medical Officer of the National MS Society (NMSS) since October 2001 and served as Chairman of the National Medical Advisory Board of the NMSS from 2001-2009. He has been a member of the NMSS Board of Directors since 2003, and was Chairman of the Clinical Advisory Committee of the New York Chapter of the NMSS from 1991-2004. He was also Chairman of the Professional Education Committee of the NMSS and is a Past President of the Consortium of MS Centers. He was the first Chairman of the Multiple Sclerosis Section of the American Academy of Neurology (AAN), and has participated in numerous clinical trials of new treatments for MS.

Dr. Miller is a member of the AAN Board of Directors, and was Editor of Continuum, their bimonthly continuing education publication, from 2003-2012 and continues to serve as Editor of Continuum Audio. Dr. Miller has served as the Principal Investigator for many clinical trials in MS and has been a member of many data and safety monitoring boards. He is the co-author of 2 books on MS and related disorders and has published many peer-reviewed articles and book chapters.

Jointly provided by Potomac Center for Medical Education and Rockpointe

This activity is supported by an educational grant from EMD Serono.

©2016 Rockpointe